Aromatase inhibitor strategies in metastatic breast cancer.

14 A nonsignificant trend toward a survival benefit was observed in favor of letrozole (34 versus 30 months, p = 0.53), however, the absence of a clear survival benefit may reflect the approximately 50% cross-over rate.

also in 5,406 other papers